BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 9692651)

  • 21. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.
    Dunstan CR; Felsenberg D; Seibel MJ
    Nat Clin Pract Oncol; 2007 Jan; 4(1):42-55. PubMed ID: 17183355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I; Kousidou OCh; Karamanos NK
    In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diphosphonates--pharmacology and clinical use].
    Aaseth J; Syversen U; Førre O
    Tidsskr Nor Laegeforen; 1998 Mar; 118(7):1064-6. PubMed ID: 9531831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue.
    Toussaint ND; Elder GJ; Kerr PG
    Clin J Am Soc Nephrol; 2009 Jan; 4(1):221-33. PubMed ID: 18987295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bisphosphonates in bone diseases.
    Sparidans RW; Twiss IM; Talbot S
    Pharm World Sci; 1998 Oct; 20(5):206-13. PubMed ID: 9820883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bisphosphonates in the prevention and treatment of glucocorticoid-induced osteoporosis.
    Blair MM; Carson DS; Barrington R
    J Fam Pract; 2000 Sep; 49(9):839-48. PubMed ID: 11032210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The application advances of bisphosphonates in bone metastasis].
    Liang P
    Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of action of bisphosphonates.
    Rodan GA
    Annu Rev Pharmacol Toxicol; 1998; 38():375-88. PubMed ID: 9597160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates and the treatment of bone disease in the elderly.
    Johansen A; Stone M; Rawlinson F
    Drugs Aging; 1996 Feb; 8(2):113-26. PubMed ID: 8845585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteonecrosis and bisphosphonates in oral and maxillofacial surgery.
    Chaudhry AN; Ruggiero SL
    Oral Maxillofac Surg Clin North Am; 2007 May; 19(2):199-206, vi. PubMed ID: 18088878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery, clinical development, and therapeutic uses of bisphosphonates.
    Licata AA
    Ann Pharmacother; 2005 Apr; 39(4):668-77. PubMed ID: 15755793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bisphosphonates: indications in bone diseases other than osteoporosis].
    Abdelmoula LC; Ben M'barek R; Ben Hadj Yahia C; Tekaya R; Testouri N; Chaabouni L; Zouari R
    Tunis Med; 2011 Jun; 89(6):511-6. PubMed ID: 21681711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neridronic acid on osteoclasts derived by physiological dual-cell cultures.
    Nicolin V; Bareggi R; Baldini G; Bortul R; Martinelli B; Narducci P
    Acta Histochem; 2007; 109(5):397-402. PubMed ID: 17574655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.
    Rosen CJ; Kessenich CR
    Drugs; 1996 Apr; 51(4):537-51. PubMed ID: 8706593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisphosphonates: pharmacology and effects on the growing skeleton.
    Papapoulos SE
    Acta Univ Carol Med (Praha); 1994; 40(1-4):29-32. PubMed ID: 9355668
    [No Abstract]   [Full Text] [Related]  

  • 40. Rationale for the use of alendronate in osteoporosis.
    Kanis JA; Gertz BJ; Singer F; Ortolani S
    Osteoporos Int; 1995 Jan; 5(1):1-13. PubMed ID: 7703618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.